Overview

Tokai Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. Our lead drug candidate, galeterone, is an oral small molecule that utilizes the mechanistic pathways of current second-generation androgen signaling inhibitors, while also introducing a distinct third mechanism – androgen receptor degradation. We are developing galeterone for the treatment of patients with metastatic castration-resistant prostate cancer.
More >>
Stock Performance TKAI (Common Stock) $1.550.00 (0.00%)09/29/164:00 p.m. ET
Stock chart for: TKAI.O.  Currently trading at $1.55 with a 52 week high of $12.93 and a 52 week low of $0.98.
Data provided by Nasdaq. Minimum 15 minutes delayed.See more
Recent NewsMore >>
  
09/08/16Tokai Pharmaceuticals Announces Review of Strategic Alternatives
BOSTON--(BUSINESS WIRE)--Sep. 8, 2016-- Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that its Board of Directors has initiated a review of strategic alternatives for the company focused on maximizing stockholder value. Potential strategic alternatives that may be explored or evaluated a... 
Download PDFPrinter Friendly Version
07/29/16Tokai Pharmaceuticals Announces Reduction in Force
BOSTON--(BUSINESS WIRE)--Jul. 29, 2016-- Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that it is reducing its workforce by approximately 60 percent, to a total of 10 full-time equivalent employees, under a plan expected to be largely completed by the end of the third quarter of 2016. This ... 
Download PDFPrinter Friendly Version
07/26/16Tokai Pharmaceuticals Announces Clinical Update
Company to Discontinue Phase 3 ARMOR3-SV Trial of Galeterone in AR-V7 Positive mCRPC Tokai to Host Conference Call Today at 8:30 AM E.T. BOSTON--(BUSINESS WIRE)--Jul. 26, 2016-- Tokai Pharmaceuticals Inc. (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that it plans to discontinue the ARMOR3-SV cli... 
Download PDFPrinter Friendly Version
EventsMore >>
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Tokai Pharmaceuticals Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 
Investor Contact
Argot Partners
E-mail: tokai@argotpartners.com

Media Contact
Ten Bridge Communications
E-mail: dan@tenbridgecommunications.com

Data provided by Nasdaq. Minimum 15 minutes delayed.
Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet